

Amendments to the specification

Please note that all page numbers and line numbers herein refer to the concurrently filed English language translation of the Japanese language specification.

Please amend the title as follows.

~~METHOD~~ METHODS OF FOR TREATING ISCHEMIC DISEASE DISEASES

Please insert the following heading and paragraph at page 1, line 5.

Cross-Reference to Related Applications

This application is the U.S. national stage application of International Application Number PCT/JP2004/000957, filed January 30, 2004, which, in turn, claims the benefit of Japanese Patent Application Serial Number 2003-040806, filed February 19, 2003.

Please amend the paragraph starting at page 6, line 17 as follows.

[3] the method according to [1] or [2], wherein ~~angiopoietin-1~~ or the vector encoding angiopoietin-1 is a viral vector ~~encoding angiopoietin-1~~;

Please amend the paragraph starting at page 6, line 22 as follows.

[6] the method according to [1] or [2], wherein ~~angiopoietin-1~~ or the vector encoding angiopoietin-1 is a naked DNA;

Please amend the paragraph starting at page 6, line 24 as follows.

[7] the method according to any one of [1] to [6], wherein ~~angiopoietin-1~~ or the vector encoding angiopoietin-1 is a vector that drives angiopoietin-1 expression using CA promoter or a promoter having a transcriptional activity equivalent to or higher than that of said CA promoter;

Please amend the paragraph starting at page 17, line 36 as follows.

In the case of a virus, ~~the dosage can be administered~~ administration may take place, for example, at one or more sites (for example, two to ten sites) in the surviving muscle (skeletal muscle, cardiac muscle, or such) surrounding the ischemic site. In the case of an adenovirus, the dosage preferably ranges from, for example,  $10^{10}$  to  $10^{13}$  pfu/body, and more preferably  $10^{11}$  to  $10^{13}$  pfu/body. The dosage of a minus-strand RNA virus preferably ranges from, for example,  $2 \times 10^5$  to  $5 \times 10^{11}$  CIU. A naked DNA can be administered at one or more sites (for example, two to ten sites) in the surviving muscle surrounding the ischemic site. The injection dosage per site preferably ranges from, for example, 10  $\mu$ g to 10 mg, and more preferably 100  $\mu$ g to 1 mg. When performing an *ex vivo* administration of cells into which a vector has been introduced, the vector is introduced into the target cells (for example, in a test tube or dish) *ex vivo*, for example, at a multiplicity of infection (MOI) of 1 to 500. In the present invention, minus-strand RNA viral vectors have been found to introduce foreign genes into mesenchymal cells with exceedingly high efficiency. Accordingly, when mesenchymal cells are used in an *ex vivo*

administration, it is preferable to use a minus-strand RNA viral vector to introduce genes into the mesenchymal cells. When Ang-1 gene-introduced cells are used, for example,  $10^5$  to  $10^9$  cells, and preferably  $10^6$  to  $10^8$  cells can be transplanted to ischemic tissues. When a protein preparation is used, it may be administered at one or more sites (for example, two to ten sites) in the surviving muscle surrounding the ischemic site. The dosage preferably ranges from, for example, 1  $\mu\text{g/kg}$  to 10  $\text{mg/kg}$ , and more preferably 10  $\mu\text{g/kg}$  to 1  $\text{mg/kg}$ . Alternatively, the vector or the protein preparation may be administered, for example, several times (one to ten times) to the artery that leads to the ischemic tissue (for example, the coronary artery of an ischemic heart). In such cases, when a protein preparation is used, the dosage per site preferably ranges from, for example, 1  $\mu\text{g/kg}$  to 10  $\text{mg/kg}$ , and more preferably 10  $\mu\text{g/kg}$  to 1  $\text{mg/kg}$ . A vector or protein preparation may be administered intravenously several times (one to ten times) or it may be administered continuously. In such cases, when a protein preparation is used, the total dosage preferably ranges from, for example, 1  $\mu\text{g/kg}$  to 10  $\text{mg/kg}$ , and more preferably 10  $\mu\text{g/kg}$  to 1  $\text{mg/kg}$ . When a vector is used, it may be administered at the same dosage as described above for the intramuscular injection. See, Freedman SB *et al.* Ann Intern Med 136:54-71 (2002), for dosage.

Please amend the paragraph starting at page 24, line 3 as follows.

In another embodiment, the cell fraction contains mesodermal ~~liver~~ stem cells with SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(-), CD34(-), and CD45(-).

Please amend the paragraph starting at page 25, line 32 as follows.

A specific example involves first mixing a solution (2 ml L-15 + 3 ml Ficoll) with a bone marrow fluid (5 µl to 10 µl) collected from vertebrate, and centrifuging the resulting mixture at 2,000 rpm for 15 minutes to separate a mononuclear cell fraction (about 1 ml). The cells were then washed by mixing the mononuclear cell fraction with a culture solution (2 ml of DMEM), and centrifuging the mixture at 2,000 rpm for 15 minutes for the second time. The supernatant is then discarded, and the precipitated cells are collected. In addition to the thighbone, the cell fractions of the present invention have sources including the sternum, and the iliac bone which constitutes the pelvis. The cell fractions can be obtained not only from these bones but also from other large bones. The cell fractions can be also collected from bone marrow fluids or cord blood ~~stored in~~ provided by bone-marrow banks. When cord blood cells are used, the cell fraction can be collected from cord blood ~~stored in~~ provided by bone-marrow banks.

Please amend the paragraph starting at page 28, line 22 as follows.

The present invention also relates to methods for producing genetically modified oral squamous cells, comprising the step of contacting oral squamous cells with a minus-strand RNA viral vector. Furthermore, the present invention also relates to methods for producing genetically modified macrophages, comprising the step of contacting macrophages with a minus-strand RNA viral vector that carries a gene. The present

invention also relates to methods for producing genetically modified dendritic cells, comprising the step of contacting dendritic cells with a minus-strand RNA viral vector that carries a gene. It was found that a minus-strand RNA viral vector can introduce genes into oral squamous cells, macrophages, and dendritic cells with an exceedingly higher efficiency, compared with an adenoviral vector which is generally expected to express high levels of an introduced gene. Thus, a minus-strand RNA viral vector is highly useful to introduce genes into oral squamous cells (including oral squamous carcinoma cells), macrophages, and dendritic cells. Specifically, the present invention relates to (i) methods for producing genetically modified oral squamous cells, comprising the step of contacting oral squamous cells with a minus-strand RNA viral vector carrying a gene; (ii) methods for producing genetically modified macrophages, comprising the step of contacting ~~dendritic cells~~ macrophages with a minus-strand RNA viral vector carrying a gene, and (iii) methods for producing genetically modified ~~macrophages~~ dendritic cells, comprising the step of contacting dendritic cells with a minus-strand RNA viral vector carrying a gene. Furthermore, the present invention also relates to genetically modified cells produced by the methods described above. Such a genetic modification of cells is useful for regulating the immune system in gene therapy for oral squamous cell carcinoma and gene therapy for cancers and immune diseases.

Please amend the paragraph starting at page 30, line 24 as follows.

Fig. 8 presents graphs showing the expression of LacZ in rat skeletal muscles (A)

and hearts (B) as a result of the injection of naked DNA. ~~An indicated amount of plasmid (20 µg) was~~ 20 µg of plasmid were injected into the femoral muscle of the lower limb or cardiac apex (n=4). β-gal activity was assayed using Galacto-light plus kit four days after the plasmid injection and is shown as ng activity of LacZ in muscle or heart. Bar represents the standard error.

Please amend the paragraph starting at page 32, line 12 as follows.

Human VEGF gene was obtained by PCR cloning of cDNA derived from a human glioma cell line U251. The nucleotide sequence of the obtained VEGF gene was confirmed by BigDye Terminator method (Perkin-Elmer). Human Ang1 gene was PCR cloned from cDNA derived from human bone marrow cells, and the nucleotide sequence was confirmed by the same procedure described above. Comparison of the determined nucleotide sequence of the Ang1 gene with that registered under the accession number U83508 in GenBank suggested that they are identical, except that the nucleotide A at position 933 had been replaced with G. Despite of the nucleotide substitution, the amino acid sequence of Ang1 protein is identical to that of U83508 in GenBank. The cloned VEGF and Ang1 cDNAs were individually inserted between the restriction sites EcoRI and BglII of a pCAcc vector (WO 02/100441; Ito., Y., *et al.* (2002) Mol Ther. 5: S162) derived from pCAGGS (Niwa, H. *et al.* (1991) Gene. 108: 193-199). Thus, the respective VEGF and Ang1 expression vectors, pCAhVEGF and pCAhAng1, were prepared. Adenoviruses expressing either VEGF or Ang1 were prepared by the COS-TPC method

developed by Saito *et al.* (Miyake, S., Proc. Natl. Acad. Sci. USA 93: 1320-1324 (1996)).

The plasmids of pCAhVEGF and pCAhAng1 were digested with a restriction enzyme ClaI. The resulting gene expression units, each comprising a VEGF or Ang1 cDNA and a CA promoter, were inserted into the ClaI restriction site of the cosmid pAxcw

(Nakamura, T. *et al.* (2002) Hum Gene Ther. 13: 613-626) comprising a portion of the adenovirus type 5 gene, to produce ~~pAxcwCAhVEGF/Ang1~~ pAxcwCAhVEGF and

pAxcwCAhAng1. A DNA-terminal protein complex (TPC) comprising

~~pAxcwCAhVEGF/Ang1~~ pAxcwCAhVEGF or pAxcwCAhAng1 and full-length adenovirus type 5 was digested with a restriction enzyme EcoT22I, and then the product was introduced into 293 cells by a calcium phosphate coprecipitation method. Plaques which contain the modified adenovirus were then harvested (Graham, F. L. and A. J. van der Eb. (1973) Virology. 52: 456-467). The adenovirus from each plaque was confirmed based on its restriction enzyme digestion pattern. Furthermore, it was confirmed by PCR that the viruses were not contaminated with the wild-type virus. Thus, the respective adenoviral vectors AxCAhVEGF and AxCAhAng1 for expressing VEGF and Ang1 were prepared.

The adenoviruses to be used for generating a rat model of myocardial infarction were purified by ultracentrifugation in a CsCl discontinuous density gradient and dialyzed against 10% glycerol/PBS (Kanegae, Y., *et al.* (1995) Nucleic Acids Res. 23: 3816-3821).

The concentrations (optical density units/ml, opu/ml) of the purified adenoviral vectors were measured by the  $A_{260}$  in the presence of 0.1% SDS and determined by using the following formula (Nyberg-Hoffman, C. *et al.* (1997) Nat Med. 3: 808-811):

$$\text{opu} = A_{260} \times (1.1 \times 10^{12})$$

Please amend the paragraph starting at page 35, line 20 as follows.

Ang1 expression in the hearts, into which the vector had been introduced, was also examined by RT-PCR (Fig. 3). The hearts were excised five days after the adenoviral vector-mediated gene introduction ( $1 \times 10^{10}$  opu/heart). Total RNAs were extracted from the left ventricular cardiac muscle using RNeasy Kit (Qiagen KK, Tokyo, Japan). To avoid DNA contamination in the total RNAs of cardiac muscle, the samples were treated with DNaseI using RNase-free DNase Set (Qiagen) according to the attached instruction. The first cDNA strands were synthesized from the total RNAs by a random priming method using a random primer mixture (Invitrogen, Carlsbad, CA) and Superscript<sup>TM</sup> II (Invitrogen). The human Ang1-specific mRNA transcribed from the adenoviral vector was detected using a forward primer that is human Ang1-specific and a reverse primer for the rabbit  $\beta$ -globulin located at the terminator site of the Ang1 expression unit. The internal control rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was also detected by RT-PCR. The human Ang1 forward primer, rabbit  $\beta$ -globulin reverse primer, and rat GAPDH primer are shown below.

Please amend the paragraph starting at page 35, line 33 as follows.

Human Ang1 primer:

Forward primer: 5'-CAGAGGCAGTACATGCTAAGAATTGAGTTA-3' (SEQ ID



NO: 6)

Rabbit  $\beta$ -globulin primer:

Reverse primer: 5'-AGATGCTCAAGGGGCTTCATGATG-3' (SEQ ID NO: 7)

~~Rabbit~~ Rat GAPDH primer:

Forward primer: 5'-TATTGGGCGCCTGGTCACCA-3' (SEQ ID NO: 8)

Reverse primer: 5'-CCACCTTCTTGATGTCATCA-3' (SEQ ID NO: 9)

Please amend the paragraph starting at page 36, line 4 as follows.

Thirty cycles of PCR were performed, and human Ang1 mRNA and rat GAPDH mRNA were detected. The resulting PCR products were separated on a 2% agarose gel. Total RNA was extracted from HeLa cells that had been infected with AxCAhAng1 at 100 opu/cell, and used as a positive control for the human Ang1 mRNA.

Please amend the paragraph starting at page 37, line 20 as follows.

The vascular densities in the infarcted site and the peri-infarct myocardium of the infarcted hearts were found to have decreased as compared with the normal hearts (Fig. 4). When VEGF or Ang1 was administered using an adenovirus, the vascular density was significantly increased in the infarcted site and the peri-infarct myocardium. In particular, the vascular density in the peri-infarct region, which is close to the site of gene administration, was increased to a level higher than in normal heart muscles (the vascular density in the peri-infarct myocardium:  $644 \pm 96$  /mm<sup>2</sup> in the Ang1-treated group,  $350 \pm 79$

/mm<sup>2</sup> in the physiological saline-treated group ( $p < 0.01$  vs the Ang1-treated group),  $332 \pm 127$  /mm<sup>2</sup> in the AxCAZ3-treated group ( $p < 0.01$  vs the Ang1-treated group), or  $402 \pm 121$  /mm<sup>2</sup> in the sham-operated group). Hemangioma was not found in the Ang1-treated group, either macroscopically or microscopically. Interestingly, the physiological saline-treated group and AxCAZ3-treated group showed a reduction in the number of blood vessels in the interventricular septum distant from the site of gene administration four weeks after myocardial infarction ( $341 \pm 60$  /mm<sup>2</sup> and  $367 \pm 113$  /mm<sup>2</sup>, respectively). The decrease in the number of septal blood vessels was suppressed by the administration of Ang1 gene ( $461 \pm 100$  /mm<sup>2</sup>) or VEGF gene ( $483 \pm 46$  /mm<sup>2</sup> in the sham-operated group). Fig. 5 shows immunostaining of vascular endothelia with the anti-CD34 MoAb. Micro vessels with diameters of 10  $\mu$ m or less, as well as blood vessels with diameters of 10  $\mu$ m or more, were found in the Ang1 gene-administered group (for every sample, many  $\alpha$ -SMA-positive blood vessels were found in the left ventricular region of the infarcted hearts treated with Ang1;  $38.9 \pm 7.35$  /mm<sup>2</sup> in the septal region,  $38.9 \pm 4.81$  /mm<sup>2</sup> in the boundary region, and  $112 \pm 26.1$  /mm<sup>2</sup> in the infarcted region). In every group except for the Ang1-treated group, there was no significant alteration in the density of  $\alpha$ -SMA-positive blood vessels with diameters greater than 10  $\mu$ m ( $19$  to  $22$  /mm<sup>2</sup>). In addition, it was found that administration of Ang1 alone increased the vascular density to the same extent as the administration of the VEGF gene (Fig. 4).

Please amend the paragraph starting at page 38, line 23 as follows.

Total left ventricle (LV) area (mm<sup>2</sup>), ~~infaretion~~ infarcted area (mm<sup>2</sup>), septal wall thickness (mm), ~~infaretion~~ infarct wall thickness (mm), epicardial and endocardial ~~circumference~~ circumferences of LV (mm), and epicardial and endocardial ~~infaretion~~ infarct length lengths (mm).

Please amend the paragraph starting at page 38, line 26 as follows.

From these results, evaluation was performed using the following formulas:

% ~~infaretion~~ infarct size = infarcted region / total LV area x 100

% Ant/septal wall thickness = anterior wall (infarct) thickness / septal wall thickness x  
100

~~Viable~~ Surviving LV area = (total LV myocardial area) - (infarcted myocardial area);

%endocardial infarct length = endocardial infarct length / endocardial circumference of  
LV x 100;

%epicardial infarct length = epicardial infarct length / epicardial circumference of LV x  
100;

Please amend the paragraph starting at page 38, line 33 as follows.

As shown in Fig. 5, clear signs of cardiac failure are observed in the infarcted cardiac muscles, including thinning of the myocardial walls in the infarct and throughout the surviving left ventricular myocardium, and tendency of left ventricular lumen

enlargement. As shown in Table 2, when compared with those of the control group, the infarct region was reduced significantly (~~% infarction~~ infarct size) and the mass of surviving myocardium increased significantly (~~% viable~~ surviving LV area) in the Ang1 gene-administered group. Thus, it was clearly shown that Ang1 has an effect on surviving myocardium, as well as an effect of reducing the size of myocardial infarct. The % infarct thickness parameter, which reflects the thickness of an infarcted wall, was also found to have significantly increased in the Ang1- administered group.

Please amend the paragraph starting at page 43, line 10 as follows.

Twenty  $\mu\text{g}$  of naked plasmid in 0.1 ml of 0.9% physiological saline was injected into the skeletal muscles or hearts of Lewis rats (male, 8-week old, 250 to 300 g weight; Sankyo Labo Service (Tokyo, Japan)) using a 1 ml syringe with a 27G injection needle. AxCAZ3 adenoviral particles (1x  $10^{10}$ ,  $5 \times 10^9$ , and 1x  $10^9$  OPU) in 0.1 ml of 0.9% physiological saline were also injected into the hearts. For the injection into skeletal muscles, the hind leg skin was incised by 2 cm long to facilitate injection into the femoral muscles (Wolff, J.A. *et al.*, Science 1990; 247: 1465-1468). For the injection into the heart, the left chest was opened and the naked plasmids or adenovirus particles were injected into the cardiac apex (Lin, H. *et al.*, Circulation 1990; 82: 2217-2221). After the injection, the incision wounds were sutured with silk sutures.

Please amend the paragraph starting at page 44, line 21 as follows.

LacZ expression levels in the heart were compared between the CA promoter-based plasmid vector and the adenoviral vector. The adenoviral vector AxCZ3 was injected into the cardiac apex at various doses (1x  $10^{10}$ ,  $5 \times 10^9$ , and 1x  $10^9$  OPU) (n= 4). After five days, the LacZ expression level in the heart, into which AxCZ3 had been injected, was compared with that in the cardiac tissues into which 20  $\mu$ g of pCZ2 had been injected. The result showed that the average expression level of the introduced gene in the heart, mediated by 20  $\mu$ g of pCZ2, was found to be comparable to that mediated by  $6.0 \times 10^9$  OPU of AxCZ3 (Fig. 9).

Please amend the paragraph starting at page 44, line 28 as follows.

pcDNA3LacZ (20 $\mu$ g), pCZ2 (20 $\mu$ g), or  $5 \times 10^9$  OPU of AxCZ3 was injected into the cardiac muscle, followed by X-gal staining. LacZ-positive muscle cells were found in all the samples from the tested groups. There were almost no LacZ-positive cells in areas surrounding the injection site of the heart samples into which pcDNA3LacZ had been injected. In contrast, when pCZ2 was used, LacZ-positive myocardial cells which have high expression levels of the gene were found sporadically in the areas surrounding the injection site. The expression level and pattern of the introduced gene in cardiac tissues, into which  $5 \times 10^9$  OPU of AxCZ3 had been injected, were similar to those in the tissues where pCZ2 had been injected. As demonstrated above, the direct administration of the plasmids results in exceedingly efficient expression of the

introduced genes in the cardiac muscle, and achieves a high-level expression almost equivalent to that with the adenoviral vector, especially when CA promoter is used.

Please amend the paragraph starting at page 47, line 33 as follows.

The results are shown in Fig. 12. As commonly known, the Ad vector-introduced foreign gene was mainly expressed in the liver after intravenous administration. The SeV vector, on the other hand, was different from the AdV; when the SeV vector was used, the reporter gene was expressed in the lung, heart, and spleen, but hardly expressed in the liver. The results shown in the Figure were obtained by using extracts from the whole organs (“lung” indicates the right lung and “kidney” indicates the right kidney). The expression level increases in the order of heart < spleen < lung with considerations given to the organ weight. The organ distribution pattern of gene expression after the intramyocardial administration was found to be nearly the same as that after the intravenous administration. Therefore, organs targeted for gene expression in other organs as a result of the SeV vector overflow were revealed to be the lung and spleen.

Please amend the paragraph starting at page 49, line 11 as follows.

Total left ventricle (LV) area (mm<sup>2</sup>), ~~infarction~~ infarcted area (mm<sup>2</sup>), septal wall thickness (mm), ~~infarction~~ infarct wall thickness (mm), epicardial and endocardial ~~circumference~~ circumferences of LV (mm), and epicardial and endocardial ~~infarction~~ infarct ~~length~~ lengths (mm).

Please amend the paragraph starting at page 49, line 14 as follows.

The size was then evaluated based on the results using the following formula.

~~%infarction~~ infarct size = infarcted region / total LV area x 100

~~%infarction~~ infarct thickness = anterior wall (~~infarction~~ infarct) thickness / septal wall thickness x 100

~~Viable~~ Surviving LV area = (total LV myocardial area) - (infarction myocardial area);

Please amend the paragraph starting at page 50, line 3 as follows.

Lewis rats (eight-week old, male, and about 300 g weight) were anesthetized by inhalation of diethyl ether and intramuscular injection of 40 mg/kg ketamine and 4 mg/kg xylazine via an upper limb. After shaving both lower limbs, the abdominal region and the left inguinal region were incised, and the ~~right~~ left iliac artery, ~~right~~ left femoral artery, and their branches were all exposed. After the ~~right~~ left iliac artery and its branches were ligated, the left femoral artery was also ligated at its origin, immediately before the bifurcation into the popliteal and saphenous arteries. Furthermore, all other branches of the left femoral artery were identified and ligated, and then the left femoral artery was removed surgically. In the operation,  $5 \times 10^7$  CIU of the SeV vector was administered at two sites on the rectus femoris muscle using a 30G needle. After confirming that there were no hemorrhages, the surgical wound was sutured to complete the operation. In the null group,  $5 \times 10^7$  CIU of SeVNull was injected instead of SeVAng1, and in the negative control group, 0.9% physiological saline was injected.

Please amend the paragraph starting at page 50, line 15 as follows.

The blood flow analysis was carried out using Laser-Doppler imaging as described below. The blood flow in the lower limb was measured continuously over two weeks after ischemia (on day 1, day 3, day 7, and day 14 after ischemia) using a Laser Doppler system (Moor LDI, Moor Instruments, Devon, United Kingdom). The rats were anesthetized by inhalation of ether, and then further anesthetized and sedated with ketamine (25 mg/kg) and xylazine (2 mg/kg). The rats were kept at 37°C for 10 minutes and then analyzed for blood flow. The continuous blood flow measurements were carried out at the identical spots in the same rats. The resulting blood flow images were analyzed to estimate the mean blood flow in the feet and gastrocnemius regions of both lower limbs. To reduce the influence of measurement conditions, the blood flow ratio of ischemic side (left lower limb) to normal side (right lower limb) (tissue blood flow ratio: blood flow on the ischemic side/blood flow on the normal side) was then calculated.

Please amend the paragraph starting at page 51, line 8 as follows.

Rat ~~cardiac~~ mesenchymal stem cells (MSC) were separated from Lewis rat thighbones according to the previous report (Tsuda, H., T. Wada, *et al.* (2003) *Mol Ther* 7(3): 354-65). Both ends of the thighbones were cut off, and bone marrows were collected by flushing the bones with 10% FBS-containing Dulbecco's modified Eagle's medium (DMEM) with an injector. The resulting bone marrow suspension was passed through 18, 20, and 22G needles successively to prepare a bone marrow cell suspension.



The obtained bone marrow cells were plated at a cell density of  $5 \times 10^7$  nucleated cells/10 cm culture dish and cultured for 4 days in culture medium (DMEM containing 10%FBS, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin, and 2 mM L-glutamine). The culture medium was changed every 3 to 4 days to remove floating cells. The adherent cells were passaged and used as rat MSCs.

Please amend the paragraph starting at page 53, line 1 as follows.

(1) ~~Cultured cell line~~ Human cervical cancer cell

Please replace the Sequence Listing found in the English language translation of PCT/JP2004/000957 with the enclosed paper copy of the Sequence Listing provided with the concurrently filed Statement Under 37 C.F.R. §§ 1.821 – 1.825.